# India Gene Therapy Market

> India Gene Therapy Market Research Report By Therapeutic Area (Oncology, Genetic Disorders, Infectious Diseases, Cardiovascular Diseases, Neurological Disorders), By Technology (Viral Vectors, CRISPR, Gene Editing, RNA Therapy, Non-Viral Methods), By Application (Research, Clinical, Commercial) and By Route of Administration (Intravenous, Intramuscular, Intradermal, Intrathecal, Oral) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 19.04%
- **2024:** $ 244.8 Million
- **2025:** $ 291.41 Million
- **2035:** $ 1,664.8 Million
- **Key Players:** Novartis (CH), Gilead Sciences (US), Sangamo Therapeutics (US), Spark Therapeutics (US), Bluebird Bio (US), CRISPR Therapeutics (CH), Bristol-Myers Squibb (US), Roche (CH), AstraZeneca (GB), Pfizer (US)

**Report ID:** MRFR/Pharma/51505-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/india-gene-therapy-market-53266

---

## Market Summary

## **India Gene Therapy Market Overview**

As per MRFR analysis, the India Gene Therapy Market Size was estimated at 258 (USD Million) in 2024.The India Gene Therapy Market Industry is expected to grow from 290.8(USD Million) in 2025 to 1,040 (USD Million) by 2035. The India Gene Therapy Market CAGR (growth rate) is expected to be around 12.283% during the forecast period (2025 - 2035)

**Key India Gene Therapy Market Trends Highlighted**

The India gene therapy market is witnessing significant market trends driven by advancements in biotechnology and increased support from the government. The Indian government is actively promoting research and development in gene therapy, recognizing its potential to address various genetic disorders that are prevalent in the country. Initiatives like "Make in India" and the establishment of regulatory frameworks to streamline approvals highlight the commitment to fostering a conducive environment for gene therapy innovations. 

Opportunities to be explored include collaboration between domestic and international research institutions, which can enhance the development of new therapies tailored to the Indian population.As genetic disorders, such as thalassemia and sickle cell anemia, are widespread in India, there is a pressing need for effective treatment options. Additionally, the growing awareness and acceptance of gene therapy among healthcare professionals and patients present further avenues for market expansion. Trends in recent times show a surge in clinical trials and research focused on personalized medicine approaches. 

Companies are increasingly developing targeted therapies that are specific to genetic mutations prevalent in the Indian demographic. Moreover, advancements in CRISPR technology and the associated reduction in costs for gene editing techniques have encouraged more players to enter the market.The integration of digital health solutions with gene therapy is also on the rise, making it easier for researchers and clinicians to track patient outcomes and enhance treatment effectiveness. Overall, these trends signify a dynamic evolution within the India gene therapy market, presenting a promising landscape for future growth and innovation.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**India Gene Therapy Market Drivers**

**Increasing Genetic Disorders and Rare Diseases Prevalence**

In India, the rise in genetic disorders and rare diseases has been a significant catalyst for the growth of the India Gene Therapy Market Industry. It is reported that around 6% to 8% of the Indian population suffers from some form of genetic disorder, which translates to over 70 million individuals affected by conditions like hemophilia, thalassemia, and muscular dystrophy. The Government of India has recognized this challenge and has initiated several programs aimed at diagnosing and treating these diseases through advanced gene therapy techniques.

Organizations such as the Indian Council of Medical Research (ICMR) have stressed the necessity of developing innovative treatment methods, further paving the way for growth in the gene therapy sector. The emerging biotechnology companies in India are rapidly entering the market, emphasizing the need for cutting-edge solutions to address these pressing health issues. This trend indicates that the demand for gene therapy solutions will continue to rise as more patients seek access to effective treatment options.

**Government Initiatives and Regulatory Support**

The Indian government is increasingly supportive of biotechnology and gene therapy initiatives, providing a conducive regulatory environment that fosters innovation. Policies such as the National Biotechnology Development Strategy aim to enhance the bio-economy of India, pushing in the direction of advanced therapies including gene therapy. For instance, approval processes have been expedited for clinical trials relating to gene therapy, which facilitates quicker market entry of new treatments.

The Department of Biotechnology (DBT) is actively supporting biotechnology research and development (R&D), including gene therapy for rare diseases, facilitating advancements and receiving government funding. This initiative positions India on the world map of gene therapy and invites investments while prompting domestic pharmaceutical companies to develop novel treatment alternatives.

**Technological Advancements in Gene Editing**

Technological advancements, particularly in gene editing technologies like CRISPR-Cas9, are playing a pivotal role in advancing the India Gene Therapy Market Industry. The expansion of these technologies has led to groundbreaking research and development, enabling scientists and researchers in India to address complex genetic issues more effectively. According to the Department of Biotechnology, Indian scientists have published over 5,000 research papers in genetic and molecular research the last decade, evidencing the rapid growth of this sector.

These advancements have not only improved the efficacy of gene therapies but have also reduced costs significantly, making therapies more accessible and appealing to the Indian populace, which is critical for addressing a large patient base suffering from hereditary conditions.

**Increased Investment and Collaborations in Gene Therapy R&D**

There is a noticeable increase in investments and collaborations in the field of gene therapy within India, driven by both public and private sectors. Major pharmaceutical companies and biotechnology firms are recognizing the potential of gene therapies and allocating significant funds toward Research and Development initiatives. The Biocon Academy, for example, has launched programs to foster collaboration between industry and academia, enhancing training and research capabilities in gene therapy.

Recent funding reports indicate that over 100 biotech startups focused on gene therapy have emerged in India within the past five years, with investments surpassing billions of dollars. This emboldens the landscape for innovation and gives rise to new therapies that can effectively mitigate genetic disorders, thereby enhancing the overall growth and future prospects of the India Gene Therapy Market.

**India Gene Therapy Market Segment Insights**

**Gene Therapy Market Therapeutic Area Insights**

The India Gene Therapy Market within the Therapeutic Area segment is experiencing substantial growth as it harnesses innovative technologies to address a wide range of diseases. With the overall industry expected to witness remarkable expansion, the focus on various conditions such as Oncology, Genetic Disorders, Infectious Diseases, Cardiovascular Diseases, and Neurological Disorders is becoming increasingly significant. Oncology, in particular, leads the way as researchers explore targeted approaches in gene manipulation to treat cancerous cells, offering hope for more effective therapies and personalized medicine.

Genetic Disorders, affecting millions in India, highlight the potential for gene therapy to correct underlying genetic defects, providing a long-term solution rather than just symptomatic relief. Infectious Diseases also play a crucial role, especially as the recent global pandemic has underscored the necessity for advanced therapeutic strategies to combat viral infections, where gene therapies could pave the way for innovative vaccines and treatments. Cardiovascular Diseases, one of the leading causes of mortality in India, benefit from gene therapy’s ability to potentially restore normal function to genetic anomalies associated with heart conditions.

Likewise, Neurological Disorders represent a market with significant unmet needs, where gene therapy may offer breakthroughs in treating conditions like Alzheimer’s and Parkinson’s, are increasing in prevalence among the aging population. Overall, the diversification within the Therapeutic Area segment of the India Gene Therapy Market showcases a dynamic landscape with vast opportunities for healthcare advancement, driven by increasing research initiatives, government support for biotechnology, and a growing recognition of the benefits of gene-based therapies.

With improved Healthcare Infrastructure and favorable policies, India is positioning itself as a major player in the gene therapy arena, enhancing treatment paradigms across various therapeutic areas and potentially transforming outcomes for patients suffering from these challenging health conditions.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Gene Therapy Market Technology Insights**

The Technology segment of the India Gene Therapy Market includes various innovative approaches, each contributing significantly to the advancement of therapeutic solutions. Viral Vectors are pivotal in delivering genetic material into cells efficiently, making them a popular choice among researchers and developers. CRISPR technology stands out due to its precision and versatility in gene editing, enabling tailored approaches for various genetic disorders. Gene Editing methodologies are expanding their applicability across different diseases, therefore holding a considerable share of the market due to their potential for targeted treatments.

RNA Therapy offers promise in addressing diseases by directly modifying RNA, presenting new avenues for treating conditions that were previously resistant to traditional methods. Non-Viral Methods, though often less prevalent, enhance safety and reduce the risk associated with gene delivery mechanisms, thereby appealing to a broader range of applications. This diverse array of technologies is crucial as the India Gene Therapy Market continues to evolve, driven by the increasing prevalence of genetic disorders, advancements in Research and Development, and supportive government initiatives aimed at boosting the biotechnology sector.

The combination of these technologies fosters innovation and creates opportunities for breakthroughs in treatment strategies within the Indian healthcare landscape.

**Gene Therapy Market Application Insights**

The Application segment of the India Gene Therapy Market plays a crucial role in advancing medical science and improving patient outcomes. This segment can be broken down into various focuses, including Research, Clinical, and Commercial applications, each contributing significantly to the overall growth of the industry. Research applications are essential as they facilitate the development of gene therapies and the exploration of genetic diseases, driving innovation and discovery in this field. In the Clinical application area, it emphasizes the translation of these innovative therapies into effective treatments for patients, showcasing the potential to cure diseases that were previously considered untreatable.

The Commercial aspect addresses the need for these therapies to reach the market successfully, ensuring accessibility for patients while driving revenue growth for companies involved. With India rapidly becoming a hub for biomedical research and innovation, the India Gene Therapy Market is expected to witness an increase, bolstered by supportive government initiatives and funding. The market growth also benefits from rising incidences of genetic disorders and a growing emphasis on personalized medicine in the healthcare system.

As the country invests more in advanced therapies and infrastructure, the Application segment will become increasingly important in shaping the future landscape of healthcare in India.

**Gene Therapy Market Route of Administration Insights**

The Route of Administration segment plays a crucial role in the overall dynamics of the India Gene Therapy Market as it significantly influences the efficacy, safety, and convenience of therapeutic treatments. Within this segment, several administration methods are emerging, including Intravenous, Intramuscular, Intradermal, Intrathecal, and Oral. Intravenous administration is often seen as advantageous due to its direct infusion into the bloodstream, offering rapid therapeutic effects.

In contrast, Intramuscular and Intradermal routes are gaining traction for localized treatment, potentially reducing systemic side effects.Intrathecal administration is vital for targeting central nervous system disorders, as it allows for direct delivery to the cerebrospinal fluid. 

Meanwhile, Oral administration may provide a non-invasive alternative, appealing to patients' preferences for ease of use. With an increasing prevalence of genetic disorders in India, the demand for diverse and effective routes of administration is on the rise. The growing emphasis on Research and Development efforts in the region is likely to propel innovations in administration techniques and enhance patient outcomes.Overall, understanding the significance of these routes can unlock substantial opportunities within the India Gene Therapy Market, fueling its future growth.

**India Gene Therapy Market Key Players and Competitive Insights**

The India Gene Therapy Market is experiencing notable advancements driven by the increasing prevalence of genetic disorders, the demand for innovative therapies, and substantial investments in biopharmaceutical research and development. Gene therapy, which focuses on correcting defective genes responsible for disease development, is emerging as a potential game-changer in addressing unmet medical needs in the country. This market is characterized by a dynamic landscape where various companies strive to establish their foothold by innovating and offering targeted solutions. 

The competition is primarily influenced by strategic partnerships, collaborations with research institutions, investments in clinical trials, and the regulatory environment that governs the approval process for new therapies. Understanding the competitive insights of this market is crucial for stakeholders to navigate the complexities and identify potential growth opportunities.BristolMyers Squibb has a significant presence in the India Gene Therapy Market, leveraging its global experience and comprehensive portfolio of innovative therapies. The company's research focus on rare genetic disorders and its strong commitment to advancing gene therapies positioned it as a formidable player within the competitive landscape. 

BristolMyers Squibb has excelled in executing clinical trials and establishing partnerships with local healthcare institutions, further strengthening its outreach and market penetration in India. The company is recognized for its robust supply chain, ensuring that its gene therapies are accessible to patients in need. This focus on accessibility, combined with a dedication to patient-centric solutions, has enhanced its reputation and competitive edge in the industry.Amgen is another prominent entity in the India Gene Therapy Market, known for its pioneering work in biotechnology and gene therapy solutions.

The company is committed to advancing innovative therapies for serious conditions, with a notable emphasis on rare diseases and metabolic disorders. 

Amgen's strengths lie in its well-established research and development capabilities, which enable it to bring breakthrough therapies to market effectively. Its strategic presence in India is bolstered by key products that cater specifically to local needs, addressing regional healthcare challenges. Furthermore, Amgen's investment in partnerships with local research institutions has facilitated the acceleration of clinical trials and data generation. The company has also explored strategic mergers and acquisitions to enhance its capabilities and expand its portfolio in the gene therapy domain, thereby solidifying its market presence and driving future growth initiatives tailored to the unique needs of the Indian populace.

**Key Companies in the India Gene Therapy Market Include**

**India Gene Therapy Market Industry Developments**

Recent developments in the India Gene Therapy Market have illustrated a growing interest and investment in innovative treatments. Notably, companies like Bristol-Myers Squibb and Amgen are expanding their presence, with ongoing Research and Development initiatives to address genetic disorders prevalent in India. In terms of mergers and acquisitions, there are no significant updates reported this year related to the specified companies. 

However, in the past few years, Gilead Sciences launched its Yescarta therapy in India in November 2021, enhancing the availability of CAR T-cell therapies. Additionally, Novartis has been actively working on advancing the accessibility of its Zolgensma gene therapy, which aims to treat spinal muscular atrophy, a genetic disease affecting infants, demonstrating commitment to tap into the Indian market. 

Recently, the market valuation for gene therapy has seen substantial growth, driven by increasing awareness and demand for personalized medicine. Furthermore, India’s regulatory body has been working on frameworks to facilitate gene therapy approvals, which should further boost innovation and market expansion. The Indian government endorses advanced biotechnological research, positioning the nation as a vital hub for gene therapy advancements in Asia.

**India Gene Therapy Market Segmentation Insights**

**Gene Therapy Market Therapeutic Area****Outlook**

**Gene Therapy Market Technology****Outlook**

**Gene Therapy Market Application****Outlook**

**Gene Therapy Market Route of Administration****Outlook**

## Market Drivers

### Advancements in Biotechnology

Technological advancements in biotechnology are significantly influencing the gene therapy market. Innovations in gene editing techniques, such as CRISPR-Cas9, are enabling more precise and effective therapies. These advancements are not only enhancing the efficacy of gene therapies but also reducing associated costs, making them more accessible to the Indian population. The biotechnology sector in India is experiencing rapid growth, with investments reaching approximately $11 billion in 2025. This influx of capital is likely to foster the development of new gene therapies, thereby expanding the market. Additionally, collaborations between academic institutions and biotech firms are expected to accelerate research and development efforts, further propelling the gene therapy market forward.

### Growing Awareness and Acceptance

The rising awareness and acceptance of gene therapy among healthcare professionals and patients are driving the market's growth. As educational campaigns and outreach programs increase, more individuals are becoming informed about the potential benefits of gene therapy. This shift in perception is crucial, as it encourages patients to seek out these innovative treatments. Additionally, healthcare providers are becoming more knowledgeable about gene therapy options, leading to increased referrals and prescriptions. The gene therapy market is likely to benefit from this growing acceptance, as more patients are willing to explore advanced treatment options for their conditions. This trend may also lead to a more robust pipeline of gene therapies being developed and brought to market.

### Government Initiatives and Funding

Government initiatives aimed at promoting healthcare innovation are playing a crucial role in the gene therapy market. The Indian government has launched various programs to support research and development in biotechnology, with funding allocations increasing by approximately 15% in recent years. These initiatives are designed to encourage the development of advanced therapies, including gene therapy. By providing financial support and creating a favorable regulatory environment, the government is likely to stimulate growth in the gene therapy market. Furthermore, public-private partnerships are emerging, which could enhance the capabilities of local firms to develop and commercialize gene therapies, ultimately benefiting patients in need.

### Rising Prevalence of Genetic Disorders

The increasing incidence of genetic disorders in India is a primary driver for the gene therapy market. With an estimated 6-8 million people affected by genetic conditions, the demand for innovative treatment options is surging. This growing patient population necessitates the development of targeted therapies, which gene therapy can provide. The Indian healthcare system is gradually recognizing the potential of gene therapy as a viable treatment option, leading to increased investments in research and clinical trials. As awareness of genetic disorders rises, healthcare providers are more likely to explore gene therapy solutions, thereby expanding the market. Furthermore, the government is likely to support initiatives aimed at addressing genetic disorders, which could further stimulate growth in the gene therapy market.

### Increased Collaboration Among Stakeholders

Collaboration among various stakeholders, including pharmaceutical companies, research institutions, and healthcare providers, is emerging as a key driver for the gene therapy market. These partnerships facilitate the sharing of knowledge, resources, and expertise, which can accelerate the development of innovative therapies. In India, collaborative efforts are becoming more common, with several joint ventures and alliances being formed to advance gene therapy research. Such collaborations can lead to more efficient clinical trials and faster regulatory approvals, ultimately benefiting patients. The gene therapy market is likely to see enhanced growth as these partnerships continue to evolve, fostering an environment conducive to innovation and development.

## Future Outlook

The [Gene Therapy Market](https://www.marketresearchfuture.com/reports/gene-therapy-market-8399) in India is projected to grow at a 19.04% CAGR from 2025 to 2035, driven by technological advancements, increasing investments, and rising disease prevalence.

**New opportunities:**

- Development of targeted gene delivery systems for rare diseases.
- Partnerships with biotech firms for innovative therapy solutions.
- Expansion of telehealth services for remote patient monitoring and consultations.

By 2035, the gene therapy market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Vector Type: Viral Vector (Largest) vs. Non-Viral Vector (Fastest-Growing)

In the India gene therapy market, the segment distribution shows that Viral Vector holds a dominant share owing to its pivotal role in delivering therapeutic genes effectively. Its established position in clinical applications and research contributes significantly to its prevalence, making it the preferred choice among therapeutics. Non-Viral Vectors, while currently smaller in market share, are gaining traction due to advancements in technology and increasing acceptance in various therapies.

Growth trends in this segment are driven by the rising prevalence of genetic disorders and the demand for effective treatment options. Non-Viral Vector is emerging as a fast-growing alternative, particularly due to its potential for safer delivery systems and lower manufacturing costs. The focus on innovative therapies and expanding applications in gene therapy further boosts this segment's appeal, pushing it toward a larger market share in the coming years.

Viral Vector (Dominant) vs. Non-Viral Vector (Emerging)

Viral Vectors are well-established in the gene therapy segment, primarily due to their efficiency in transducing specific cell types and facilitating sustained gene expression, which is crucial for long-term therapeutic effects. Commonly used viral vectors include adenoviruses, lentiviruses, and adeno-associated viruses, which have been validated in various clinical trials. In contrast, Non-Viral Vectors, such as liposomes and nanoparticles, are emerging as competitive alternatives due to their lower immunogenicity and ease of production. They are particularly attractive for therapeutic applications that require a more controlled delivery mechanism or when viral vectors are deemed unsuitable. The increasing investment in research and development for Non-Viral systems indicates a promising future for this category, aiming for a significant share of the market.

### By Gene Type: Cytokine (Largest) vs. Tumor Suppressor (Fastest-Growing)

In the India gene therapy market, the distribution of market share among various gene types showcases Cytokine as the largest segment due to its critical role in immune response and therapeutic applications. Following closely are Tumor Suppressor genes, which, while holding a smaller share, are gaining significant traction among researchers and biotech firms for their potential in cancer treatment protocols. Other segments like Antigen and Growth Factors also contribute to the landscape but do not match the prominence of these two groups.

Growth trends indicate a robust expansion for Cytokine-based therapies, particularly for autoimmune and inflammatory disorders. Tumor Suppressor genes are rapidly becoming the focus of clinical trials as researchers explore innovative ways to combat cancer. Increased investment in biopharmaceuticals and rising incidences of genetic disorders are driving the growth of these segments, with regulatory support also enhancing the development process for emerging therapies.

Cytokine (Dominant) vs. Tumor Suppressor (Emerging)

Cytokines are pivotal in mediating immune responses and currently dominate the gene type segment as they facilitate a variety of therapeutic processes. Their ability to influence immune system functions makes them a preferred choice for treating chronic diseases. On the other hand, Tumor Suppressor genes represent an emerging area of interest focused on preventing tumor formation. These genes show promise in innovative cancer therapies, with researchers exploring ways to reactivate these pathways in aged or cancerous cells. As clinical applications expand, these segments reflect a dynamic interplay between well-established and innovative therapeutic strategies within the India gene therapy market.

### By Application: Oncological Disorders (Largest) vs. Rare Diseases (Fastest-Growing)

The application segment of the India gene therapy market is characterized by diverse needs, with oncological disorders holding the largest market share. This segment is crucial due to the rising incidence of cancer, which drives demand for innovative therapeutic solutions. Rare diseases, while comprised of smaller patient populations, are gaining significant traction as advancements in gene therapy technologies improve treatment accessibility and efficacy.

Growth trends in this segment are primarily fueled by increased investment in research and development, as well as a favorable regulatory environment that encourages innovation. Additionally, public awareness surrounding genetic disorders is growing, prompting healthcare providers to seek more effective therapeutic options. The emergence of personalized medicine is also a critical driver, particularly in the treatment of rare diseases, making this a dynamic area of growth in the market.

Oncological Disorders (Dominant) vs. Rare Diseases (Emerging)

Oncological disorders represent a dominant segment in the India gene therapy market, primarily due to the high prevalence of various cancers that require targeted treatments. The advancements in gene editing technologies, such as CRISPR and viral vectors, have paved the way for more effective therapies that can specifically target cancerous cells, making these options increasingly favorable among healthcare professionals. In contrast, rare diseases are emerging as a key focus within the market. Although they affect a small number of patients, the development of gene therapies tailored for specific genetic conditions is becoming more prevalent, driven by the potential for significant patient outcomes and the promise of regulatory incentives for developers. This dual focus on oncological and rare diseases creates a balanced yet competitive landscape in the gene therapy sector.

### By Delivery Method: In Vivo Gene Therapy (Largest) vs. Ex Vivo Gene Therapy (Fastest-Growing)

In the India gene therapy market, the delivery method segment is characterized by a distinctive division between In Vivo and Ex Vivo gene therapies. In Vivo gene therapy currently holds the largest market share, favored for its effectiveness and convenience in directly delivering therapeutic agents into the patient's body. On the other hand, Ex Vivo gene therapy, while having a smaller share, is rapidly gaining traction due to its innovative approach of altering cells outside the body before reintroducing them, appealing to a niche but growing customer base.

Growth trends reveal that the Ex Vivo segment is outpacing In Vivo therapies, attributed to advancements in gene editing technologies and increased investment in research and development. Factors driving this growth include a rising incidence of genetic disorders and the demand for personalized medicine, bolstering interest in treatments that involve modifying patient cells. The versatility and safety profile associated with Ex Vivo techniques are expected to further enhance their appeal over the forecast period.

In Vivo Gene Therapy (Dominant) vs. Ex Vivo Gene Therapy (Emerging)

In Vivo gene therapy is characterized by its direct delivery mechanism, which allows for precise targeting of affected cells, making it the dominant approach in the India gene therapy market. This method enjoys a broader acceptance due to its ability to administer therapies through various means such as vectors, which can efficiently penetrate tissues. In contrast, Ex Vivo gene therapy is emerging as a promising alternative, essential for complex cases where specific genetic modifications are needed before reintroduction. While traditionally more labor-intensive and costly, innovations are reducing barriers to entry, enhancing its growth prospects. The strategic focus on safety and personalized treatment further positions Ex Vivo as a competitive player, attracting investments and interest from biotechnology firms.

## Competitive Benchmarking

The gene therapy market in India is currently characterized by a dynamic competitive landscape, driven by rapid advancements in biotechnology and increasing investments in research and development. Key players are focusing on innovation and strategic partnerships to enhance their market presence. Notably, Novartis (CH) has been actively pursuing collaborations with local biotech firms to leverage regional expertise and accelerate the development of gene therapies. Similarly, Gilead Sciences (US) is concentrating on expanding its portfolio through acquisitions and partnerships, particularly in the area of rare genetic disorders, which appears to be a growing segment within the market. These strategies collectively contribute to a competitive environment that is increasingly focused on innovation and localized solutions.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and improve supply chain efficiency. This approach not only enhances responsiveness to market demands but also aligns with regulatory requirements in India. The market structure is moderately fragmented, with several players vying for dominance. However, the influence of major companies like Novartis (CH) and Gilead Sciences (US) is substantial, as they set benchmarks for innovation and operational excellence that smaller firms often strive to emulate.

In August  Novartis (CH) announced a strategic partnership with a leading Indian biotech firm to co-develop a novel gene therapy targeting a rare genetic disorder prevalent in the region. This collaboration is significant as it not only enhances Novartis's local capabilities but also demonstrates a commitment to addressing unmet medical needs in India. The partnership is expected to expedite the clinical development process, thereby positioning Novartis favorably in a competitive market.

In September  Gilead Sciences (US) launched a new gene therapy product aimed at treating a specific type of inherited retinal disease. This launch is particularly noteworthy as it underscores Gilead's strategy to diversify its offerings and tap into niche markets. The introduction of this therapy is likely to strengthen Gilead's foothold in the Indian market, especially given the increasing prevalence of genetic disorders in the region.

In October  CRISPR Therapeutics (CH) reported a successful clinical trial for its gene-editing therapy aimed at treating beta-thalassemia, a common blood disorder in India. This milestone is crucial as it not only validates CRISPR's innovative approach but also enhances its credibility in the market. The success of this trial may lead to increased investment and interest in gene therapies, further intensifying competition among key players.

As of November  the competitive trends in the gene therapy market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in research and development processes. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex regulatory landscapes and accelerating product development. Looking ahead, competitive differentiation is likely to evolve from traditional price-based strategies to a focus on innovation, technological advancements, and supply chain reliability, reflecting a broader shift in the industry towards sustainable and patient-centric solutions.

## Recent News & Developments

Recent developments in the India Gene Therapy Market have illustrated a growing interest and investment in innovative treatments. Notably, companies like Bristol-Myers Squibb and Amgen are expanding their presence, with ongoing Research and Development initiatives to address genetic disorders prevalent in India. In terms of mergers and acquisitions, there are no significant updates reported this year related to the specified companies. 

However, in the past few years, Gilead Sciences launched its Yescarta therapy in India in November 2021, enhancing the availability of CAR T-cell therapies. Additionally, Novartis has been actively working on advancing the accessibility of its Zolgensma gene therapy, which aims to treat spinal muscular atrophy, a genetic disease affecting infants, demonstrating commitment to tap into the Indian market. 

Recently, the market valuation for gene therapy has seen substantial growth, driven by increasing awareness and demand for personalized medicine. Furthermore, India’s regulatory body has been working on frameworks to facilitate gene therapy approvals, which should further boost innovation and market expansion. The Indian government endorses advanced biotechnological research, positioning the nation as a vital hub for gene therapy advancements in Asia.

## Report Scope

| MARKET SIZE 2024 | 244.8(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 291.41(USD Million) |
| MARKET SIZE 2035 | 1664.8(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 19.04% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Novartis (CH), Gilead Sciences (US), Sangamo Therapeutics (US), Spark Therapeutics (US), Bluebird Bio (US), CRISPR Therapeutics (CH), Bristol-Myers Squibb (US), Roche (CH), AstraZeneca (GB), Pfizer (US) |
| Segments Covered | Vector Type, Gene Type, Application, Delivery Method |
| Key Market Opportunities | Advancements in gene editing technologies enhance treatment options in the gene therapy market. |
| Key Market Dynamics | Regulatory advancements and technological innovations drive growth in the gene therapy market, enhancing treatment accessibility and efficacy. |
| Countries Covered | India |

## Frequently Asked Questions

**Q: What is the current valuation of the India gene therapy market?**
A: The market valuation was $244.8 Million in 2024.

**Q: What is the projected market size for the India gene therapy market by 2035?**
A: The projected valuation for 2035 is $1664.8 Million.

**Q: What is the expected CAGR for the India gene therapy market during the forecast period 2025 - 2035?**
A: The expected CAGR is 19.04% during the forecast period.

**Q: Which companies are the key players in the India gene therapy market?**
A: Key players include Novartis, Gilead Sciences, Sangamo Therapeutics, and others.

**Q: What are the main segments of the India gene therapy market?**
A: The main segments include Vector Type, Gene Type, Application, and Delivery Method.

**Q: How did the Viral Vector segment perform in 2024?**
A: The Viral Vector segment was valued at $146.4 Million in 2024.

**Q: What is the valuation of the Ex Vivo Gene Therapy segment in 2024?**
A: The Ex Vivo Gene Therapy segment was valued at $164.8 Million in 2024.

**Q: Which application segment had the highest valuation in 2024?**
A: The Rare Diseases application segment had the highest valuation at $50.0 Million in 2024.

**Q: What is the projected growth for the Non-Viral Vector segment by 2035?**
A: The Non-Viral Vector segment is projected to reach $664.8 Million by 2035.

**Q: What are the anticipated trends in gene therapy applications in India?**
A: Anticipated trends suggest growth in applications for Oncological Disorders and Neurological Disorders.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-gene-therapy-market-53266*